Scholar IQ
Try ScholarIQ free
Upload Records Snowball Search Search OpenAlex
About the database
ScholarIQanswers from OpenAlex

A randomised phase II study investigating durvalumab in addition to an anthracycline taxane-based neoadjuvant therapy in early triple-negative breast cancer: clinical results and biomarker analysis of GeparNuevo study

PaperCitations, authors & open-access status

A randomised phase II study investigating durvalumab in addition to an anthracycline taxane-based neoadjuvant therapy in early triple-negative breast cancer: clinical results and biomarker analysis of GeparNuevo study is a paper indexed in ScholarIQ from OpenAlex. ScholarIQ records 706 citations, 2019 year and closed oa status.

706
Citations
2019
Year
closed
OA Status

Related on ScholarIQ

Jens‐Uwe Blohmer
Author
Annals of Oncology
Journal
Breast Cancer Treatment Studies
Topic
Breast Cancer Treatment Studies
Topic
Cancer Immunotherapy and Biomarkers
Topic
Cancer Treatment and Pharmacology
Topic
470M+ articles · free account